Evidence map›Paper›PMID 38400935›Full record

ReviewClinical and experimental nephrology2024

Urine oxygenation predicts COVID-19 risk.

Eisei Noiri, Daisuke Katagiri, Yusuke Asai, Takeshi Sugaya, Katsushi Tokunaga

Registry-linked trialAbstract readReview
In one paragraph

Review in Clinical and experimental nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04681040 (Monitoring of COVID-19 Using Urine POC Kit), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04681040 unknown statusnot on this map

Monitoring of COVID-19 Using Urine POC Kit

TypeobservationalSponsorNational Center for Global Health and Medicine, JapanRan2020 to 2024Enrolled964ConditionsCovid19, Urine, Biomarker, Acute Respiratory Failure With Hypoxia
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Eisei NoiriNational Center Biobank Network (NCBN), Central Biobank, National Center for Global Health and Medicine (NCGM), 1-21-1 Toyama, Shinjuku, Tokyo, 162-8655, Japan. noiri-tky@umin.ac.jp.ORCID http://orcid.org/0000-0002-9515-7582
Daisuke KatagiriDepartment of Nephrology, National Center for Global Health and Medicine, Tokyo, Japan.
Yusuke AsaiAntimicrobial Resistance Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine (NCGM), Tokyo, Japan.
Takeshi SugayaNephrology, St Marianna University, Kawasaki, Japan.
Katsushi TokunagaNational Center Biobank Network (NCBN), Central Biobank, National Center for Global Health and Medicine (NCGM), 1-21-1 Toyama, Shinjuku, Tokyo, 162-8655, Japan.

Funding

Japan Agency for Medical Research and Development 20he0822003j0001National Center for Global Health and Medicine 20A2013National Center for Global Health and Medicine 21A2002
6 · The paper itself

Abstract

Since February, 2023, the omicron variant has accounted for essentially all new coronavirus infections in Japan. If future infections involve mutant strains with the same level of infectivity and virulence as omicron, the government's basic policy will be to prevent the spread of infection, without compromising socioeconomic activities. Objectives include protecting pregnant women and elderly persons, and focusing on citizens requiring hospitalization and those at risk of serious illness, without imposing new social restrictions. Although the government tries to raise public awareness through education, most people affected by COVID-19 stay at home, and by the time patients become aware of the seriousness of their disease, it has often reached moderate or higher severity. In this review, we discuss why this situation persists even though the disease seems to have become milder with the shift from the delta variant to omicron. We also propose a pathophysiological method to determine the risk of severe illness. This assessment can be made at home in the early stages of COVID-19 infection, using urine analysis. Applicability of this method to drug discovery and development is also discussed.

Indexed as

COVID-19SARS-CoV-2HumansOxygenRisk AssessmentRisk FactorsUrinalysisOxygenAcute respiratory distress syndrome (ARDS)FABP1L-type fatty acid-binding protein (L-FABP)Systemic inflammatory response syndrome (SIRS)Urine

Identifiers

PMID38400935
PMCPMC11189954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.